Actionable Insight
Into Your Child's Health
ReadyGen is an at-home pediatric screening test that empowers parents to further protect their children by delivering personalized health information on many conditions that can’t be detected by standard prenatal tests or state newborn screenings.* Through our partnership with Sema4, a health intelligence company using advanced genomic testing, families will receive two tests for the price of one.
ReadyGen Pediatric Screening
Early detection of 200+ conditions through advanced DNA sequencing technology**
Actionable information: all conditions can be managed with diet, medication, or other therapies (including 20+ addressable with newborn stem cells)
Requires only a cheek swab—noninvasive and easy!
ReadyGen Pharmacogenomic Testing
Analyzes your child’s response or sensitivity to 40+ medications‡
Provided to your child’s doctor to help recommend personalized medications in the future
Requires only a cheek swab—noninvasive and easy!
Pediatric Screening
200+ genetic conditions, including 20+ conditionstreatable with newborn stem cells. See sample report
- Beta thalassemia
- Congenital amegakaryocytic thrombocytopenia
- Dyskeratosis congenita
- Fanconi anemia
- Sickle Cell Disease
- Wilms Tumor
- Adenosine deaminase deficiency
- Congenital neutropenia
- Chronic granulomatous disease
- Omenn syndrome
- Gaucher disease
- Hunter syndrome (MPS-II)
- Hurler syndrome (MPS-IH)
- Krabbe Disease
- Mannosidosis
- Maroteaux-Lamy Syndrome (MPS-VI)
- Morquio Syndrome (MPS-IV)
- Mucolipidosis II (I-cell Disease)
- Neuronal Ceroid Lipofuscinosis (Batten Disease)
- Niemann-Pick Syndrome
- Sanfilippo Syndrome (MPS-III)
- Scheie Syndrome (MPS-IS)
- Tay Sachs Disease
- X-Linked Adrenoleukodystrophy
Pharmacogenomic Testing
Analyzes your child's response or sensitivity to 40+ medications, allowing your doctor to create a personalized treatment plan. See sample report- Celecoxib (CYP2C9)
- Codeine (CYP2D6)
- Hydrocodone (CYP2D6)
- Oxycodone (CYP2D6)
- Tramadol (CYP2D6)
- Aminoglycosides (MT-RNR1)
- Warfarin (CYP2C9, VKORC1)
- Fosphenytoin (CYP2C9)
- Phenytoin (CYP2C9)
- Ondansetron (CYP2D6)
- Voriconazole (CYP2C19)
- Amitriptyline (CYP2D6, CYP2C19)
- Citalopram (CYP2C19)
- Clomipramine (CYP2D6, CYP2C19)
- Desipramine (CYP2D6)
- Doxepin (CYP2D6, CYP2C19)
- Escitalopram (CYP2C19)
- Fluoxetine (CYP2D6)
- Fluvoxamine (CYP2D6)
- Imipramine (CYP2D6)
- Nortriptyline (CYP2D6)
- Paroxetine (CYP2D6)
- Sertraline (CYP2C19)
- Trimipramine (CYP2D6, CYP2C19)
- Simvastatin (SLCO1B1)
- Antineoplastic Agents
- Capecitabine (DPYD)
- Fluorouracil (DPYD)
- Mercaptopurine (TPMT)
- Thioguanine (TPMT)
- Clopidogrel (CYP2C19)
- Aripiprazole (CYP2D6)
- Iloperidone (CYP2D6)
- Pimozide (CYP2D6)
- Atazanavir (UGT1A1)
- Azathioprine (TPMT)
- Tacrolimus (CYP3A5)
- Eliglustat (CYP2D6)
- Atomoxetine (CYP2D6)
Order your kit today
Requires only a cheek swab—noninvasive and easy.
*Worldwide, approximately 1 in 27 children screen positive for a genetic condition on the ReadyGen panel. If your child screens positive, a genetic counselor will contact you to discuss the results of the test and help you navigate next steps. The chance of a positive result varies depending on ethnicity.
**All of the genes have a well-established relationship with disease and meet eligibility criteria as set by ClinGen guidelines (https://clinicalgenome.org/start/ PMID: 28552198).
‡Evidence supporting associations between variants and drug response is obtained from a combination of sources, including: FDA drug labeling, guidelines written by a consortium of international experts (such as CPIC), and peer-reviewed research literature.
*Worldwide, approximately 1 in 27 children screen positive for a genetic condition on the ReadyGen panel. If your child screens positive, a genetic counselor will contact you to discuss the results of the test and help you navigate next steps. The chance of a positive result varies depending on ethnicity.
**All of the genes have a well-established relationship with disease and meet eligibility criteria as set by ClinGen guidelines (https://clinicalgenome.org/start/ PMID: 28552198).
‡Evidence supporting associations between variants and drug response is obtained from a combination of sources, including: FDA drug labeling, guidelines written by a consortium of international experts (such as CPIC), and peer-reviewed research literature.